Home/ Stocks/ ANAB

AnaptysBio, Inc. Common Stock

ANAB XNAS

$69.33 +2.37 (+3.54%) ▲ 15-min delayed

Open

$66.92

High

$70.07

Low

$66.01

Volume

490.5K

Market Cap

$2.02B

About AnaptysBio, Inc. Common Stock

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Sector: PHARMACEUTICAL PREPARATIONS Employees: 104 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$234.60M	$-13,232,000	$-0.46
FY 2025	$234.60M	$-13,232,000	$-0.46
Q3 2025	$76.32M	$15.11M	$0.54
Q2 2025	$22.26M	$-38,630,000	$-1.34

Earnings & Analyst Ratings

Next Earnings: Tue, Aug 4, 2026

Calendar →

Related Market News

No specific coverage for ANAB yet. Check out our latest market news or earnings calendar.

Get ANAB Alerts

Stay ahead with breaking news, price alerts, and expert analysis on AnaptysBio, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.